Oaktree Acquisition CORP Iii Life Sciences

Oaktree Acquisition Corp. III Life Sciences announced the resignation of its CFO, Thomas Sweeney, and the immediate appointment of George A. Martinez as his successor.

Oaktree Acquisition Corp. III Life Sciences announced the appointment of Dr. David A. Berry, a seasoned life sciences executive, as an independent director to its board.

Oaktree Acquisition Corp. III Life Sciences announced the resignation of CFO Courtney Conigliaro and the immediate appointment of Thomas Sweeney, a seasoned financial executive from Oaktree Capital Management, as her successor.

Oaktree Acquisition Corp. III Life Sciences reports the resignation of a director and the appointment of a new chairman and director.

Oaktree Acquisition Corp. III Life Sciences will allow separate trading of its Class A ordinary shares and warrants starting December 16, 2024.

Oaktree Acquisition Corp. III Life Sciences has partially exercised its over-allotment option, resulting in additional gross proceeds of $17.3 million and the forfeiture of some Class B shares.

Oaktree Acquisition Corp. III Life Sciences reports net income of $1.39 million for Q1 2026, driven by trust account interest, while continuing its search for a business combination.

Oaktree Acquisition Corp. III Life Sciences reported a net income of $1.97 million for Q3 2025, driven by trust account interest, but faces substantial doubt about its ability to continue as a going concern.

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported a net income of $1.87 million for Q2 2025, primarily from trust account interest, as it continues its search for a business combination target.

Oaktree Acquisition Corp. III Life Sciences reports a net income of $1.66 million for the quarter ended March 31, 2025, driven by interest earned on cash held in trust.

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported net income for 2025 but faces substantial doubt about its ability to continue as a going concern due to its business combination deadline.

Oaktree Acquisition Corp. III Life Sciences outlines the terms and conditions of its securities, including ordinary shares, warrants, and units, in its latest 10-K filing.

Oaktree Acquisition Holdings III LS, LLC reports changes in beneficial ownership of Oaktree Acquisition Corp. III Life Sciences shares following the partial exercise of the underwriters' over-allotment option.

Oaktree Acquisition Corp. III Life Sciences, a blank check company targeting the healthcare sector, files an amendment to its S-1 registration statement for a $175 million initial public offering.

Oaktree Acquisition Corp. III Life Sciences, a blank check company affiliated with Oaktree Capital, aims to raise $175 million in an IPO to pursue a business combination within the healthcare industry.

Fort Baker Capital Management LP, along with Steven Patrick Pigott and Fort Baker Capital, LLC, has disclosed a 5.1% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported beneficial ownership of 6.2% of Oaktree Acquisition Corp III Life Sciences' Class A ordinary shares as of March 31, 2026.

Barclays PLC has reported a 4.35% beneficial ownership stake in Oaktree Acquisition Corp I-A, holding 861,625 common shares as of December 31, 2025.

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 4.1% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a 1.4% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences, holding 277,689 Class A Ordinary Shares.

The Healthcare of Ontario Pension Plan Trust Fund (HOOPP) has disclosed a 3.5% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences, holding 700,000 Class A ordinary shares.